StemRIM Inc. (4599.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

108.1x

EV/EBITDA

−7.3x

Market Cap

JPY 19.51B

MomentumView details →

1D Return

+0.32%

YTD Return

+18.63%

RSI (14)

40.8

ValuationView details →

P/E (Fwd)

108.1x

EV/EBITDA

−7.3x

Market Cap

JPY 19.51B

RSI (14)

40.8

MomentumView details →

1D Return

+0.32%

YTD Return

+18.63%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−27.52%

ROA (TTM)

−26.56%

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

+13.24%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+5.52%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

53.71x

Quick Ratio

53.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

−1.90B

Op. CF (TTM)

—

Next earningsSep 9, 2026 →

Latest newsMore news →

Stemrim obtained a patent in South Korea for a stem cell gene therapy for epidermolysis bullosa.57d ago

Similar companies

Fuso Pharmaceutical Industries,Ltd.4538.T CanBas Co.,Ltd.4575.T Innovacell Inc.504A.T Renascience Inc.4889.T AnGes,Inc.4563.T RaQualia Pharma Inc.4579.T Find similar companies →

Latest newsMore news →

Stemrim obtained a patent in South Korea for a stem cell gene therapy for epidermolysis bullosa.57d ago